Gossamer Bio (NASDAQ:GOSS) Posts Quarterly Earnings Results

Share on StockTwits

Gossamer Bio (NASDAQ:GOSS) issued its earnings results on Tuesday. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.10), Bloomberg Earnings reports.

Shares of GOSS traded down $0.04 during trading hours on Thursday, hitting $21.79. The company had a trading volume of 24,839 shares, compared to its average volume of 522,988. The company has a market capitalization of $1.50 billion and a PE ratio of -0.96. The company has a current ratio of 17.80, a quick ratio of 17.80 and a debt-to-equity ratio of 0.09. Gossamer Bio has a one year low of $14.49 and a one year high of $25.06. The company’s fifty day moving average price is $18.28 and its two-hundred day moving average price is $19.44.

In other Gossamer Bio news, Director Faheem Hasnain bought 10,000 shares of Gossamer Bio stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $16.80 per share, with a total value of $168,000.00. Also, insider Luisa Salter-Cid sold 50,000 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $19.88, for a total value of $994,000.00. The disclosure for this sale can be found here. Over the last three months, insiders bought 40,821 shares of company stock valued at $275,497 and sold 450,000 shares valued at $9,668,719. Insiders own 23.30% of the company’s stock.

GOSS has been the subject of several research reports. Zacks Investment Research cut Gossamer Bio from a “hold” rating to a “sell” rating in a report on Tuesday, August 20th. Evercore ISI set a $30.00 target price on Gossamer Bio and gave the stock a “buy” rating in a report on Monday, August 12th. ValuEngine cut Gossamer Bio from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Berenberg Bank assumed coverage on Gossamer Bio in a research report on Wednesday, October 30th. They issued a “buy” rating and a $31.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $28.50.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Story: Options Trading – Understanding Strike Price

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Genedrive’s  Buy Rating Reiterated at Peel Hunt
Genedrive’s Buy Rating Reiterated at Peel Hunt
Grainger’s  “Buy” Rating Reiterated at Peel Hunt
Grainger’s “Buy” Rating Reiterated at Peel Hunt
Hurricane Energy  Stock Rating Reaffirmed by Berenberg Bank
Hurricane Energy Stock Rating Reaffirmed by Berenberg Bank
Joules  Stock Rating Reaffirmed by Peel Hunt
Joules Stock Rating Reaffirmed by Peel Hunt
Yum China Holdings Inc  Receives Consensus Rating of “Buy” from Analysts
Yum China Holdings Inc Receives Consensus Rating of “Buy” from Analysts
Head-To-Head Analysis: Netlist  versus NVE
Head-To-Head Analysis: Netlist versus NVE


 
© 2006-2019 Zolmax.